Zantac (Ranitidine) is recalled

Date: April 2, 2020

The FDA has recalled Zantac (Ranitidine) from pharmacy's shelves.  The recall applies to both tablets and the prescription suspension for babies.

The FDA questions whether a chemical, called NDMA, is present in the Zantac in harmful amounts.  NDMA is reported to be a "probable carcinogen" if you have prolonged exposure.  For some reason, the amount of NDMA sometimes increases over time as the Zantac sits in the medicine cabinet.  The FDA does not know for sure that the Zantac (ranitidine) has a dangerous amount of NDMA, but it's recommending alternatives until they can find out for sure.

In my practice, I have no information of anyone ever getting sick from the NDMA in Zantac. I've heard no case reports of anyone whose cancer was linked to their longterm use of Zantac. I have no patients, over the past 3 decades, who have had cancer after taking Zantac. The FDA's concern now is only theoretical, and they say they may return the Zantac to the shelves once they investigate further, if they find no concern after all.

For our patients, we will be switching from Zantac to Pepcid (Famotidine, any age) or Axid (Nizatidine, over 6 months).  Please let us know if your insurance doesn't cover it as well as the Zantac.

For more information, click here for a news report:

     --  Dr. Epstein